Hana Biosciences, Inc. (NASDAQ: HNAB), a South San Francisco, CA-based biopharmaceutical company, is focused on the acquisition, development and commercialization of novel products to strengthen the foundation of cancer care. The company is dedicated to creating value by accelerating the development of lead product candidates, building a best-in-class team, expanding its pipeline, and nurturing a unique company culture. For further information, visit the Company’s web site at www.hanabiosciences.com.
- 18 years ago
QualityStocks
Hana Biosciences, Inc. (NASDAQ: HNAB)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Belden Inc. (NYSE: BDC) To Acquire RUCKUS Networks for $1.85 Billion
Belden (NYSE: BDC) announced it has entered into a definitive agreement to acquire RUCKUS Networks from Vistance Networks for approximately $1.85…
-
From Capital to Catalysts: Canamera Energy Metals Corp.’s (CSE: EMET) (OTCQB: EMETF) $10M Raise Sets the Stage for Rare Earth Exploration Momentum
Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF)and may include paid…
-
Forward Industries Inc. (NASDAQ: FWDI) Adds Digital Asset and Traditional Finance Executive Mark Brazier as Chief Financial Officer
Forward Industries has appointed experienced financial executive Mark Brazier to serve as Chief Financial Officer.…